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Health Economics Unit, School of Health & Population Sciences, University of Birmingham, Birmingham, Edgbaston, UKA B S T R A C TObjectives: To report ﬁndings from a systematic review, this article
sought to address two related questions. First, how has the practice of
UK pediatric cost-utility analyses evolved over time, in particular how
are health-related outcomes assessed and valued? Second, how do
the methods compare to the limited guidance available, in particular,
the National Institute for Health and Care Excellence (NICE) reference
case(s)? Methods: Electronic searches of MEDLINE, Embase, and
Cochrane databases were conducted for the period May 2004 to April
2012 and the Paediatric Economic Database Evaluation database for
the period May 2004 to December 2010. Identiﬁed studies were
screened by three independent reviewers. Results: Forty-three stud-
ies were identiﬁed, 11 of which elicit utility values through primary
research. A discrepancy was identiﬁed between the methods used for
outcome measurement and valuation and the methods advocated
within the NICE reference case. Despite NICE recommending the useee front matter Copyright & 2014, International S
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gham, Edgbaston B15 2TT, UK.of preference-based instruments designed speciﬁcally for children,
most studies that were identiﬁed had used adult measures. In fact,
the measurement of quality-adjusted life-years is the aspect of
economic evaluation with the greatest amount of variability and the
area that most digressed from the NICE reference case. Conclusions:
Recommendations stemming from the review are that all studies
should specify the age range of childhood and include separate
statements of perspective for costs and effects as well as the
reallocation of research funding away from systematic review studies
toward good quality primary research measuring utilities in children.
Keywords: economic evaluation, health-related quality of life,
literature review, pediatric, utility.
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In the United Kingdom, the National Institute for Health and
Care Excellence (NICE) operates as a decision-making body by
making treatment recommendations for the UK National Health
Service on the basis of economic and clinical evidence. NICE
advocates a standardized approach to economic evaluation to
ensure comparability of results and consistency of decision
making [1]. To facilitate this process, NICE has issued a “refer-
ence case” for all technology assessment economic evaluations
to adhere to. The reference case includes recommendations for
the adoption of a National Health Service/Personal Social Serv-
ices perspective for costs; the use of the quality-adjusted life-
year (QALY), measured using the EuroQol ﬁve-dimensional (EQ-
5D) questionnaire; the application of a 3.5% discount rate to both
costs and outcomes; and, where appropriate, the use of proba-
bilistic sensitivity analysis and a lifetime time horizon [1].
Results are expressed in terms of “cost per QALY” gained, andthe difference in costs and QALYs is expressed as an incremental
cost-effectiveness ratio.
Although the reference case is designed to ensure quality and
consistency, there are certain population subgroups in which a
straightforward application of this “reference case” is problem-
atic, with the evaluation of health interventions for children
being one example. There are many well-documented reasons
[2,3] why child health should be conceptualized differently to
adult health, such as the rapid rate of development in childhood;
dependency on parents or other caregivers; differences between
children and adults in terms of disease epidemiology and treat-
ment focus [4,5]; and differences in access to, and uptake of,
health care resources. It may also be inappropriate to apply
preference values that have been elicited for descriptions of
health states experienced by adults with in the context of health
interventions targeted at children.
Indeed, NICE acknowledge that some adjustments will need to
be made to the standard reference case when assessing the cost-ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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“reference case” has changed over time in relation to guidelines
for the practice of pediatric cost-utility analysis (CUA). NICE’s
2004 reference case speciﬁes the use of a generic preference-
based instrument to assess quality of life but proposes no
modiﬁcations for pediatric CUA [6]. The 2008 reference case
speciﬁes that:
When necessary, consideration should be given to alternative
standardised and validated preference-based measures of
HRQL, such as the Health Utility Index 2 (HUI 2), that have
been designed speciﬁcally for use in children. [7]
HUI is a family of preference-based instruments that com-
prises two versions, HUI2 and HUI3. A scoring system applies for
children aged 5 years and older and is under development for
children aged 3 to 5 years. It is recommended that where
possible, the HUI3 should be used for primary studies.
No speciﬁc instrument was suggested by NICE’s Decision
Support Unit in 2011 [8], and likewise, no speciﬁc instrument
was advocated for pediatric CUA in the 2013 guidance [1], which
simply reiterates that
[C]onsideration should be given to alternative standardised
and validated preference-based measures of health-related
quality of life that have been designed speciﬁcally for use in
children.
Therefore, from a methodological perspective, there remains
no deﬁnitive, clear guidance on which instrument is the most
appropriate to use for measuring health-related quality of life in
children. There is disagreement about the age range to which
generic preference-based instruments can be applied, and there
is also little consensus regarding the extent to which proxy scores
should be used for children across a broad age range between the
“very young” and adolescence [9]. Eiser and Morse [9] describe a
range of generic preference-based instruments. The recently
developed Child Health Utility 9D (CHU-9D) [10] is one of few
child-focused instruments that can claim to meet NICE’s speci-
ﬁcation of being “designed speciﬁcally for use in children” [1]. In
other cases, adjustments have been made to existing adult
instruments such as the EQ-5D youth version questionnaire,
which was derived from the EQ-5D 3 level questionnaire [11].
Published systematic reviews have noted an increase in the
annual number of pediatric [2,4,5,12] evaluations but with respect
to the methods used, Griebsch et al. [4] argue that the limited use
of generic preference-based instruments means that incremental
cost-effectiveness ratios generated by pediatric CUA are not
comparable across diseases and patient groups. Griebsch et al.
[4] conclude that the limited use of generic preference-based
instruments represents either a reﬂection of how underdevel-
oped methods are in CUA pediatric practice or a failure of the
guidelines to keep up to date with standards in CUA pediatric
evaluations.
This article reports a systematic literature review with two
distinct objectives:1. To report how methods within UK pediatric CUAs have
evolved over time, assessing in particular whether methodo-
logical and design issues noted previously by Griebsch et al. in
a review of studies to 2004 persist over the period 2004 to 2012.2. To describe and assess the relationship between pediatric
CUAs in the United Kingdom and the pediatric CUA recom-
mendations set out by NICE, particularly in relation to the
derivation of utility values.
A supplementary objective was to assess whether methods
used in published pediatric CUAs indicate a need foramendments to NICE Technology Assessment methods guidance
to improve consistency and to ensure that the guidelines are in
line with “best practice.”Methods
Search Strategy
Electronic searches were undertaken using MEDLINE, Embase,
and Cochrane databases for the period from May 2004 to April
2012 and the Paediatric Economic Database Evaluation database
for the period May 2004 to December 2010, which was the most
recent complete year available. An upper age limit of 16 years
was selected to ensure compatibility with the rationale outlined
by Griebsch et al. [4]. Search terms were developed in MEDLINE,
and adapted to Embase, using a combination of Medical Subject
Heading terms and free text. Three groups of search terms related
to 1) children, infants, and pediatric; 2) economic evaluation/
quality of life; and 3) the UK. The focus of interest was children,
for whom there are fewer validated instruments and proxy
measurement is common; therefore, practice is more varied. Full
details of the searches can be found in the online appendices (see
Appendix A in Supplemental Materials found at http://dx.doi.org/
10.1016/j.jval.2014.02.007). Search terms were modiﬁed for rele-
vant Cochrane databases.Selection
All identiﬁed studies were screened by three independent
reviewers. First, titles were screened for obvious rejection on
the basis of the exclusion criteria; then, all abstracts were
screened. If there was uncertainty regarding the rejection of the
article, then full text was requested. Inclusion criteria were
deﬁned as follows: CUA entailing the generation of a QALY score, including
health technology assessment Analysis includes children aged 16 years and younger and
measures health utility in relation to disease sequelae in this
age group Includes children in any part of the United Kingdom
 English language
 Human only
 Primary CUA or a combination of systematic review and
primary CUA
 Full manuscript publication available
Identiﬁed studies that failed to match the inclusion criteria
were excluded. Where the abstract met the inclusion criteria, the
full manuscript was requested. Any differences in opinion
regarding the inclusion of articles were resolved by discussion
between the reviewers. A citation search was undertaken for
publications included in the review to identify any additional
publications that might not have been previously identiﬁed.Assessment and Data Extraction
Data extraction criteria (see Appendix C in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2014.02.007) were devel-
oped from checklists for evaluation of adult CUA [13] combined
with criteria from the Paediatric Quality Assessment Question-
naire [14] and the framework adopted by a previous review [4].
Where possible, data extraction queries were framed in a binary or
restricted list format. Methods used for derivation of utility scores
within the economic evaluation were the focus of the review.
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After the elimination of duplicates, the search strategy identiﬁed
76 titles and abstracts. These 76 articles were retrieved for
assessment, and 41 publications were identiﬁed for inclusion in
the ﬁnal review. A further 2 articles were identiﬁed from citation
searches. Data were therefore extracted from 43 articles (see
Appendix B in Supplemental Materials found at http://dx.doi.org/
10.1016/j.jval.2014.02.007).Table 1 – Study characteristics in relation to the
assessment and valuation of HRQOL.
Source of utility values n %
Only generic preference-based described 23 51
Generic preference-based þ disease
speciﬁc
6 13
SG 6 13
Not speciﬁed 3 7
TTO 3 7
Expert opinion 2 4
Disease speciﬁc with utility mapped 1 2
Various 1 2
Utility assessment technique used n %
EQ-5D questionnaire 9 19
HUI2 6 13
SG 6 13
EQ-5D questionnaire modiﬁed 5 10
TTO 4 8
HUI3 3 6
Not speciﬁed 3 6
HUI3 modiﬁed 2 4
IHQL and expert panel 2 4
Index of well-being 2 4
QWB 2 4
None 1 2
TTO and VAS 1 2
Various 1 2
VAS 1 2
Utility score derived from n %
Child 28 60
Adult (not speciﬁed as parent) 12 26
Not speciﬁed 3 6
Child and adult 2 4
Parent 1 2
Various 1 2
QOL assessment performed by n %
Parents or caregivers 16 33
HCPs 12 24
Not speciﬁed 10 20
Self-assessment 8 16
Not applicable 2 4
Various 1 2
EQ-5D, EuroQol ﬁve-dimensional; HCP, health care practitioner;
HRQOL, health-related quality of life; HUI, health utilities index;
IHQL, Index of Health-Related Quality of Life; QOL, quality of life;
QWB, Quality of Well-Being Scale; SG, standard gamble; TTO, time
trade-off; VAS, visual analogue scale.Study Characteristics
Full study characteristics for all the included articles are available in
a supplementary online ﬁle for Web publication; a summary is
presented in Table 1. It was possible to determine details of the study
population in all 43 studies. It was found that 30 studies targeted
children exclusively, while 13 studies also included adults. Overall,
the reporting of the details of the childhood population was poor,
with no explicit deﬁnition of upper and lower age range in 23 of the
43 (53%) studies (Table 2). Most of the identiﬁed studies contained a
decision-analytic model (38 of 43 studies), and none adopted a purely
societal perspective. The time horizon was justiﬁed either explicitly
or by inference in 36 of 43 (80%) studies, and a lifetime horizon was
adopted in 17 of 43 (40%) studies. With respect to objective two, the
evidence indicated conformity to the NICE guidelines that were
applicable at the time each study was published (either the reference
case guidelines from 2004 or 2008) in all aspects of evaluation
unrelated to utility. Perspective was stated explicitly, or easily
inferred, in all but one study, and the perspective selected is that
of the NHS in 36 of 43 (86%) studies. The studies also conformed to
the NICE reference case in terms of time horizon, discount rates, and
probabilistic sensitivity analysis. Therefore, it would appear that
there is evidence of conformity to NICE standards in all aspects of
the identiﬁed CUAs that do not pertain to utility measurement.
Critical Assessment of Outcome Measures
It was found that utility estimates were generated from primary
research in 11 of 43 (26%) studies. Two CUAs were difﬁcult to
classify: Martin et al. [15] provide evidence of utility generation in a
separate publication by the same authors, whereasWalker et al. [16]
offer insufﬁcient detail on utility sources to enable classiﬁcation.
The majority of CUAs obtained utility scores by proxy using either
parent or health care professionals, and more than 25% of the
studies applied utility scores derived from adults. Wide variation
with utility assessment was observed with respect to the use of the
standard gamble approach, the EQ-5D questionnaire (modiﬁed or
unmodiﬁed), and the use of various versions of the HUI.
Although 11 of the 43 (26%) CUAs used primary research (see
Appendix D in Supplemental Materials found at http://dx.doi.org/
10.1016/j.jval.2014.02.007), only 1 study, Baguelin et al. [17],
applied utility scores to children’s own self-assessed/reported
health states in an 11 to 18 year age group (Table 2); completion
in younger children was by proxy. Those CUAs that focused on
both adults and children did not report different methods of
generating utility scores and of the 14 CUAs that derive utility
scores from adults, 5 do not highlight the limitations of this
approach (Table 2).Discussion
In areas unrelated to utility assessment, the review shows that
the methods applied within UK-based pediatric CUA conform to
the NICE reference case guidance, but with utility assessment,
there is wide variation in methodological practice.
There has been a growth in the use of preference-based
instruments in children, but NICE’s suggestion to use the HUI2 in
2008 is matched in application by no increase in its use, but instead
an increase in the use of the EQ-5D questionnaire. The 2013 NICE
guidance calls for instruments speciﬁcally developed for use with
children; the review has shown that instruments such as the CHU-
9D have never been used; and while the EQ-5D questionnaire was
modiﬁed in four CUAs, the modiﬁed version does not relate to the
EQ-5D youth version questionnaire. It should, however, be
acknowledged that with newly developed instruments such as
the CHU-9D, there is always a time lag between application of the
instrument within studies and subsequent publications.
Table 2 – Summary of studies identiﬁed as meeting the inclusion criteria.
First author
(year)
Principle
funding
source?
Health intervention Deﬁnition of
child (age
range)
speciﬁed?
(yes/no)
Age range
of patient
group (y)
QOL assessed
by
Utility values
derived via
Utility
value
elicited
for
Describes
limitations of
available evidence
with respect to
utility values
Baguelin
(2010) [17]
DOH Vaccination against inﬂuenza No o1–10 Proxy (parent) Modiﬁed EQ-5D
questionnaire
Child No
11–18 Self-assessment Modiﬁed EQ-5D
questionnaire
Child
o18
hospitalized
Self-assessment VAS Adult
Bamford
(2007) [24]
NIHR Hearing screening NA 4–6 Self-assessment HUI3 Adult No
Proxy (health
care provider)
TTO
Barton (2006)
[25]
MRC and
NGO
Cochlear implants NA 3 and 6 Proxy (parent) Modiﬁed HUI3 Child Yes
Bond (2009)
[26]
NIHR Cochlear implants Yes 1, 8 Proxy (parent) Modiﬁed HUI3 Child No
Brown (2009)
[27]
? Extracorporeal membrane
oxygenation (ECMO)
Yes 1–18 Proxy (health
care provider)
Expert opinion
(based on HUI2
health states)
Child No
Christensen
(2010) [28]
Industry Treatment of children born
short for gestational age
No NS Self-assessment EQ-5D
questionnaire
Adult No
Claxton
(2004) [29]
NIHR Treatment of UTIs Yes NS Self-assessment Index of Well-being Adult No
Colquitt
(2011) [30]
NIHR Bone-anchoring hearing aids Yes NS NA HUI3 Adult Yes
Connock
(2006) [31]
NIHR Enzyme replacement therapy for
type I Gaucher’s disease
No Birth cohort NS TTO Adult Yes
Cottrell
(2008) [32]
Industry Attention deﬁcit/hyperactivity
disorder
No NS Proxy (parent) SG Child No
Craig (2011)
[33]
NIHR Comparison of growth screening
referral strategies
No 5þ NS IHQL and expert
panel
Child Yes
Dretzke
(2011) [34]
NIHR Adalimumab and inﬂiximab for
Crohn’s disease
No NS Self-assessment TTO Adult Yes
Epps (2005)
[35]
NIHR Hydrotherapy for juvenile
rheumatoid arthritis
Yes 4–19 Proxy (parent) EQ-5D
questionnaire
Child Yes
Fayter (2007)
[36]
NIHR Monitoring of growth No 4þ NS IHQL and expert
panel
Child
and
adult
Yes
Monitoring of obesity 11þ NA None Adult
Frew (2007)
[37]
? Antiepileptic drugs Yes 3–18 Proxy (health
care provider)
Expert opinion
(based on health
states from
Child Yes
continued on next page
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Table 2 – continued
First author
(year)
Principle
funding
source?
Health intervention Deﬁnition of
child (age
range)
speciﬁed?
(yes/no)
Age range
of patient
group (y)
QOL assessed
by
Utility values
derived via
Utility
value
elicited
for
Describes
limitations of
available evidence
with respect to
utility values
modiﬁed EQ-5D
questionnaire)
Garside
(2005) [38]
NIHR Pimecrolimus in atopic
dermatitis
Yes 2–16 Proxy (parent) SG Child Yes
Healy (2011)
[39]
Industry Tacrolimus ointment in atopic
dermatitis
No NS Proxy (parent) SG Child No
Jit (2007) [40] DOH Vaccination for rotavirus
gastroenteritis
Yes 40–5 Proxy (parent or
caregiver—
unclear)
HUI2 Child No
Karnon
(2008) [41]
Industry Oral deferasirox in patients with
chronic iron overload
No NS NS QWB Adult No
King (2006)
[42]
NIHR Methylphenidate in
combination with behavioral
therapy
Yes 6 Proxy (parent) SG Child Yes
Martin (2009)
[15]
Industry Vaccination with RIX4414 to
prevent rotavirus
gastroenteritis
Yes 40–o18 mo Proxy (GP) Modiﬁed EQ-5D
questionnaire
Child Yes— develops own
data18 mo to 5 y Proxy (hospital
physician)
Melegaro
(2004) [43]
DOH Universal vaccination with
pneumococcal conjugate
vaccine
No o6 mo, 6–
11 mo, and
5 y age
bands
Various Various Various Yes
Nuijtjen
(2007) [44]
Industry Palivizumab for prevention of
respiratory syncytial virus
(RSV)
Yes r35 wk of
gestation
Proxy (parent) HUI2 Child No
Petrou (2010)
[45]
NIHR and
DOH
Topical intranasal steroids for
otitis media
Yes 4–11 Proxy (parent) HUI3 Child No
Pitt (2006)
[46]
NIHR Pimecrolimus in atopic
dermatitis
No NS Proxy (parent) SG Child No
Prasad (2009)
[47]
Industry Treatment of attention deﬁcit/
hyperactivity disorder
No NS Proxy (parent) SG Child No
Price (2011)
[48]
NIHR Controller therapy in asthma
and add-in therapy for
uncontrolled asthma
Yes 12–80 NS EQ-5D
questionnaire
Child No
Punekar
(2010) [49]
Industry Inﬂiximab in children with
severe active Crohn’s disease
Yes 6–17 Self-assessment EQ-5D
questionnaire
Adult Yes
Proxy (hospital
physician)
Expert opinion Child
Rautenberg
(2012) [50]
Industry Racecadotril plus oral
rehydration solution (ORS) vs.
ORS alone
Yes 40–o18 mo Proxy (GP) Modiﬁed EQ-5D
questionnaire
Child No
18 mo to 5 y Proxy (hospital
physician)
NIHR No Child Yes
continued on next page
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Renfrew
(2009) [51]
Enhanced staff contact
promoting breast-feeding
Birth cohort
weighing
o2500 g
Proxy (hospital
physician)
EQ-5D
questionnaire
Rice (2010)
[52]
NIHR Enhanced staff contact
promoting breast- feeding
No Birth cohort
weighing
o2500 g
Proxy (hospital
physician)
EQ-5D
questionnaire
Child Yes
Simpson
(2005) [53]
? Screening for cystic ﬁbrosis No From birth
to death
Other QWB Child
and
adult
No
Summerﬁeld
(2010) [54]
? Bilateral vs. unilateral cochlear
implants
Yes 6 Proxy (experts
and parents of
children
without
hearing
difﬁculties)
TTO and VAS Child Yes
Takeda (2010)
[55]
NIHR Growth hormone in short
stature children
No 7–10 Proxy (study
nurse)
EQ-5D
questionnaire
Adult Yes
van Hoek
(2012) [56]
DOH Vaccination program against
varicella or varicella and
herpes zoster
No NS (Proxy) parent HUI2 Parent No
Verdian
(2010) [57]
Industry Adjunctive therapy for children
with Lennox-Gastaut
No NS NS TTO NS Yes— develops own
data
Walker (2011)
[16]
NIHR Omalizumab plus high-dose
inhaled corticosteroids (ICS)
and long-acting beta agonist
(LABA) vs. ICS plus LABA
alone
Yes 6–11 NS NS NS NA
Wang (2008)
[58]
NIHR Palivizumab prophylaxis against
RSV vs. standard care in
infants
Yes 428 wk of gestational age Proxy (parent) HUI2 Child
Wang (2011)
[22]
NIHR Palivizumab prophylaxis against
RSV in high-risk infants
No r24 wk to
Z35 wk
of
gestational age Proxy (parent) HUI2 Child
Whiting
(2006) [59]
NIHR Diagnostic testing for UTI No o5 Self-assessment Index of Well-being Adult Yes
Wilson, Price
(2010) [60]
NIHR Add-on therapies to ICS for
asthma
No 12–80 NS EQ-5D
questionnaire
Child No
Wilson, Sims
(2010) [61]
NIHR Initial asthma controller therapy No 12–80 NS EQ-5D
questionnaire
Child No
Yao (2006)
[62]
NIHR MMF, MPS, and sirolimus for
renal transplant graft
rejection
Yes o18 NS NS NS Yes
DOH, Department of Health; EQ-5D, EuroQol ﬁve-dimensional; GP, general practitioner; HUI, health utilities index; IHQL, Index of Health-Related Quality of Life; MMF, mycophenolate mofetil;
MPS, mycophenolate sodium; MRC, Medical Research Council; NA, not applicable; NGO, nongovernmental organization; NIHR, National Institute for Health Research; NS, not speciﬁed; QWB,
Quality of Well-Being Scale; SG, standard gamble; TTO, time trade-off; UTI, urinary tract infection; VAS, visual analogue scale.
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V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 4 5 4 – 4 6 1460With almost every study identiﬁed it was apparent that there
is a paucity of utility data in children, which raises an important
issue about the allocation of research funding. Given this wide
issue of data unavailability, it is recommended that future
research funding be targeted toward high-quality primary
research studies that focus on generating utility data directly
from children instead of relying on reviews of poor evidence.
Although this review was focused on children rather than
adolescents, ﬁndings have shown that there is little consensus in
the literature on the upper age range of childhood, with ages
between 16 and 24 years considered in different contexts
[4,18–20]. Birth cannot be assumed the starting age for childhood;
for example, different gestational ages are used by three respira-
tory syncytial virus studies [21–23]. With this in mind, it should
not be recommended that guidance specify an age range of
childhood because such a deﬁnition varies according to the
disease context and the type of health care provision being
evaluated. In more than half of our identiﬁed studies, the age
range for childhood was not reported, so the assumed point of
transition from childhood to adulthood is not known. This creates
challenges when attempting to use published data for long-term
decision-analytic modeling of treatment, and these challenges
need to be considered when a lifetime horizon is recommended.
So, rather than specifying an age range for childhood, it is instead
recommended that published pediatric CUAs deﬁne, at the very
least, the age range they have used for children.
This review has compared the practice of CUA within the
United Kingdom against the NICE reference case guidance. A
limitation of this approach is that some of the CUAs included in
the review have not been conducted to inform NICE recommen-
dations and thus there is no reason why they would conform to
NICE guidance. We believe that the strength of economic evalua-
tion for decision making rests on consistency in methodology. It
is noteworthy that almost all the CUAs identiﬁed in this review
follow NICE guidance in areas unrelated to utility data regardless
of their objectives in relation to NICE; for example, 57% of the
identiﬁed CUAs use a discount rate of 3.5% for effects, but there is
no similar consistency for the derivation and application of utility
scores. If economic evaluation results are to be used to inform
resource allocation decisions across different disease and treat-
ment contexts, then it is fundamental that we strive for consis-
tency in methods in all areas, including assessment of utility
scores. It is recommended that future research funding be
focused on high-quality methodological studies in children and
on studies that generate utility data for childhood populations.
This will help move forward methods in this underdeveloped
area, which will, in turn, help organizations such as NICE achieve
the consistency that is required.
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